The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Göran Skog

Göran Skog

Senior lecturer

Göran Skog

Long-term biokinetics and radiation exposure of patients undergoing 14C-glycocholic acid and 14C-xylose breath tests.

Author

  • Mikael Gunnarsson
  • Sigrid Leide Svegborn
  • Kristina Stenström
  • Göran Skog
  • Lars-Erik Nilsson
  • Ola Thorsson
  • Ragnar Hellborg
  • Sören Mattsson

Summary, in English

The (14)C-glycocholic acid and (14)C-xylose breath tests are clinically used for the diagnosis of intestinal diseases, such as bacterial overgrowth in the small intestine. The two tests have in earlier studies been thoroughly evaluated regarding their clinical value, but due to the long physical half-life of (14)C and the limited biokinetic and dosimetric data, which are available for humans, several hospitals have been restrictive in their use. The aim of this study was to investigate the long-term biokinetics and dosimetry of the two (14)C compounds in patients and volunteers, using the highly sensitive accelerator mass spectrometry (AMS) technique. Eighteen (18) subjects were included, 9 for each compound. The (14)C content in samples from exhaled air, urine, and, for some subjects, also feces were analyzed with both liquid scintillation counting (LSC) and AMS. The results from the glycocholic acid study showed that, up to 1 year after the administration, 67%+/-6% (mean+/-standard deviation) of the administered activity was recovered in exhaled air, 2.4%+/-0.4% was found in urine, and 7.6% (1 subject) in feces. In the xylose study, the major part was found in the urine (66%+/-2%). A significant part was exhaled (28%+/-5%), and the result from an initial 72-hour stool collection from 2 of the subjects showed that the excretion by feces was insignificant. The absorbed dose to various organs and tissues and the effective dose were calculated by using biokinetic models, based on a combination of experimental data from the present study and from earlier reports. In the glycocholic acid study, the highest absorbed dose was received by the colon (1.2 mGy/MBq). In the xylose study, the adipose tissue received 0.8 mGy/MBq. The effective dose was estimated to 0.5 (glycocholic acid) and 0.07 mSv/MBq (xylose). Thus, from a radiation protection point of view, we see no need for restrictions in using the two (14)C-labeled radiopharmaceuticals on adults with the activities normally administered (0.07-0.4 MBq).

Department/s

  • Medical Radiation Physics, Malmö
  • Nuclear physics
  • Quaternary Sciences
  • Clinical Physiology and Nuclear Medicine, Malmö

Publishing year

2007

Language

English

Pages

762-771

Publication/Series

Cancer Biotherapy & Radiopharmaceuticals

Volume

22

Issue

6

Document type

Journal article

Publisher

Mary Ann Liebert, Inc.

Topic

  • Cancer and Oncology

Status

Published

Research group

  • Medical Radiation Physics, Malmö
  • Clinical Physiology, Malmö
  • AMS, Nuclear Physics

ISBN/ISSN/Other

  • ISSN: 1557-8852